Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls.

Cancer Res Treat · 2017 · PMC5654176 · PMID 28111427

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

For example, the BRCA1 p.Leu1780Pro variant that was present in 1.5% of cases, was marginally significant (OR, 19.5; 95% CI, 1.1 to 331.5) when 622 Korean controls from KRGDB were used.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.